Kim W Benner1, Priya Prabhakaran2, Autumn S Lowros1. 1. Samford University McWhorter School of Pharmacy, Birmingham, Alabama. 2. Division of Pediatric Critical Care, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
OBJECTIVES: To determine the proportion of infections caused by extended-spectrum ß-lactamase (ESBL)-producing Klebsiella or Escherichia coli Gram-negative organisms in the pediatric intensive care unit (PICU), and to identify risk factors for these infections. METHODS: A retrospective, single-center chart review of patients admitted to a PICU in a 5-year period with infections caused by Klebsiella species or E coli was completed. Data collected include demographics, length of stay, outcome, and relevant risk factors previously defined in the literature. RESULTS: A total of 110 isolates were cultured from 94 patients. A total of 53% of the isolates were E coli, and the remainder were Klebsiella subspecies. Of the 110 isolates, 13 isolates (11.8%) in 7 patients were ESBL positive. The ESBL-producing isolates were equally distributed amongE coli and Klebsiella and were primarily cultured from tracheal aspirates. Most of the ESBL-positive isolates (9 of 13; 69%) were cultured from patients who received ceftazidime and/or cefotaxime in the preceding 30 days. Patients infected with E coli had higher PRISM 1 scores and were more likely to have a Foley catheter, whereas infections with Klebsiella were more common in mechanically ventilated males. Although not statistically significant, 80% of patients who were infected with non-ESBL-producing organisms survived to hospital discharge versus 57% of those infected with ESBL-producing E coli and Klebsiella. CONCLUSIONS: Almost 12% of E coli and Klebsiella isolates in this patient population tested positive for ESBL production. ESBL production was equally distributed between E coli and Klebsiella species. These organisms were cultured from 7% of the study patients. As reported in previous studies, patients infected with ESBL-producing organisms most often had received prior cephalosporins and had a longer length of stay in the PICU.
OBJECTIVES: To determine the proportion of infections caused by extended-spectrum ß-lactamase (ESBL)-producing Klebsiella or Escherichia coli Gram-negative organisms in the pediatric intensive care unit (PICU), and to identify risk factors for these infections. METHODS: A retrospective, single-center chart review of patients admitted to a PICU in a 5-year period with infections caused by Klebsiella species or E coli was completed. Data collected include demographics, length of stay, outcome, and relevant risk factors previously defined in the literature. RESULTS: A total of 110 isolates were cultured from 94 patients. A total of 53% of the isolates were E coli, and the remainder were Klebsiella subspecies. Of the 110 isolates, 13 isolates (11.8%) in 7 patients were ESBL positive. The ESBL-producing isolates were equally distributed amongE coli and Klebsiella and were primarily cultured from tracheal aspirates. Most of the ESBL-positive isolates (9 of 13; 69%) were cultured from patients who received ceftazidime and/or cefotaxime in the preceding 30 days. Patients infected with E coli had higher PRISM 1 scores and were more likely to have a Foley catheter, whereas infections with Klebsiella were more common in mechanically ventilated males. Although not statistically significant, 80% of patients who were infected with non-ESBL-producing organisms survived to hospital discharge versus 57% of those infected with ESBL-producing E coli and Klebsiella. CONCLUSIONS: Almost 12% of E coli and Klebsiella isolates in this patient population tested positive for ESBL production. ESBL production was equally distributed between E coli and Klebsiella species. These organisms were cultured from 7% of the study patients. As reported in previous studies, patients infected with ESBL-producing organisms most often had received prior cephalosporins and had a longer length of stay in the PICU.
Entities:
Keywords:
antibiotic resistance; extended spectrum beta-lactamase; pediatric intensive care unit
Authors: D A Schiappa; M K Hayden; M G Matushek; F N Hashemi; J Sullivan; K Y Smith; D Miyashiro; J P Quinn; R A Weinstein; G M Trenholme Journal: J Infect Dis Date: 1996-09 Impact factor: 5.226
Authors: Steev Loyola; Luz R Gutierrez; Gertrudis Horna; Kyle Petersen; Juan Agapito; Jorge Osada; Paul Rios; Andres G Lescano; Jesus Tamariz Journal: Am J Infect Control Date: 2016-04-07 Impact factor: 2.918
Authors: Lukose K Thampy; Kenneth E Remy; Andrew H Walton; Zachery Hong; Kelilah Liu; Rebecca Liu; Victoria Yi; Carey-Ann D Burnham; Richard S Hotchkiss Journal: PLoS One Date: 2018-06-26 Impact factor: 3.240
Authors: Edwin Barrios-Villa; Gerardo Cortés-Cortés; Patricia Lozano-Zaraín; Margarita María de la Paz Arenas-Hernández; Claudia Fabiola Martínez de la Peña; Ygnacio Martínez-Laguna; Carmen Torres; Rosa Del Carmen Rocha-Gracia Journal: Ann Clin Microbiol Antimicrob Date: 2018-12-10 Impact factor: 3.944